Last reviewed · How we verify
NCT06325384: VISION-RWE
Real World Evaluation of Lifelight®: A Contactless Vital Signs Monitor for Self-monitoring Blood Pressure and Its Comparison to Standard of Care
NA trial testing Lifelight in Hypertension in 500 participants. Currently enrolling.
31 October 2025
Quick facts
| Lead sponsor | Xim Limited |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 500 |
| Start date | 10 February 2025 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Lifelight
- Blood Pressure Cuff
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
Xim Limited
Who can join
Adults 18 to 100, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomised controlled trial for comparison of real-world feasibility and clinical outcomes of two different methods of home blood pressure monitoring Participants aged 18 years or over with diagnosed and treated hypertension (including via lifestyle interventions) that is not controlled (i.e. in-clinic measurement is 140/90 mmHg or greater) will be recruited from hypertension hospital clinics
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06325384
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lifelight
Trials testing the same drug.
- NCT06535152 — Lifelight Non-Invasive Blood Pressure and Heart Rate Validation Study · NA · completed
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Xim Limited trials
Trials by the same sponsor.
- NCT06535152 — Lifelight Non-Invasive Blood Pressure and Heart Rate Validation Study · NA · completed
- NCT05850013 — The Measurement of Vital Signs in Children by Lifelight® Software in Comparison to the Standard of Care · completed
- NCT04763746 — The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of Care - Multi-site Development · completed
- NCT04589923 — The VISION-Acute Study · completed
- NCT03998098 — A Single Center Study to Demonstrate the Safety and Performance of Lifelight® First Software Application · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06325384 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xim Limited
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06325384.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing